DE3681428D1 - Stoerungen von karbohydraten in viren oder virusantigenen und verwendung in diagnostischen, prophylaktischen und/oder therapeutischen anwendungen. - Google Patents

Stoerungen von karbohydraten in viren oder virusantigenen und verwendung in diagnostischen, prophylaktischen und/oder therapeutischen anwendungen.

Info

Publication number
DE3681428D1
DE3681428D1 DE8686402610T DE3681428T DE3681428D1 DE 3681428 D1 DE3681428 D1 DE 3681428D1 DE 8686402610 T DE8686402610 T DE 8686402610T DE 3681428 T DE3681428 T DE 3681428T DE 3681428 D1 DE3681428 D1 DE 3681428D1
Authority
DE
Germany
Prior art keywords
perturbation
virusantigens
carbohydrates
prophylactic
viruses
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE8686402610T
Other languages
English (en)
Inventor
A Gerard Quash
John Dennis Rodwell
Thomas Joseph Mckearn
Jean-Pierre Ripoll
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Sante et de la Recherche Medicale INSERM
Cytogen Corp
Original Assignee
Institut National de la Sante et de la Recherche Medicale INSERM
Cytogen Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR8517377A external-priority patent/FR2590674B1/fr
Application filed by Institut National de la Sante et de la Recherche Medicale INSERM, Cytogen Corp filed Critical Institut National de la Sante et de la Recherche Medicale INSERM
Application granted granted Critical
Publication of DE3681428D1 publication Critical patent/DE3681428D1/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16722—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE8686402610T 1985-11-25 1986-11-25 Stoerungen von karbohydraten in viren oder virusantigenen und verwendung in diagnostischen, prophylaktischen und/oder therapeutischen anwendungen. Expired - Fee Related DE3681428D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR8517377A FR2590674B1 (fr) 1985-11-25 1985-11-25 Nouveaux reactifs de diagnostic
US06/928,631 US4853326A (en) 1985-11-25 1986-11-18 Carbohydrate perturbations of viruses or viral antigens and utilization for diagnostic prophylactic and/or therapeutic applications

Publications (1)

Publication Number Publication Date
DE3681428D1 true DE3681428D1 (de) 1991-10-17

Family

ID=26224838

Family Applications (1)

Application Number Title Priority Date Filing Date
DE8686402610T Expired - Fee Related DE3681428D1 (de) 1985-11-25 1986-11-25 Stoerungen von karbohydraten in viren oder virusantigenen und verwendung in diagnostischen, prophylaktischen und/oder therapeutischen anwendungen.

Country Status (8)

Country Link
EP (1) EP0229546B1 (de)
AT (1) ATE67314T1 (de)
AU (1) AU592142B2 (de)
DE (1) DE3681428D1 (de)
ES (1) ES2038597T3 (de)
FI (1) FI873233A (de)
GR (1) GR3003323T3 (de)
WO (1) WO1987003206A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4863730A (en) * 1986-03-21 1989-09-05 Cenfold Holdings, S.A. Immunotherapy for AIDS patients
EP0364492A1 (de) * 1987-06-30 1990-04-25 The Upjohn Company Virusproteine mit reduzierter o-glykosylierung
DE3884811T2 (de) * 1987-08-11 1994-02-24 Univ Minnesota Hyperimmun globulin gegen hiv.
US5164481A (en) * 1989-08-23 1992-11-17 Iaf Biochem International Inc. Peptides and analogues and mixtures thereof for detecting and eliciting antibodies to rubella virus
US5427792A (en) * 1989-08-23 1995-06-27 Biochem Immunosystems, Inc. Peptides, analogues and mixtures thereof for detecting and eliciting antibodies to the E1 and E2 protein of rubella virus
DE4025499A1 (de) * 1990-08-11 1992-02-13 Sandoz Ag Verwendung der antikoerper br55-2, deren derivate, konjugate und fragmente zur bekaempfung von hiv-infektionen
EP2289547B1 (de) 2003-09-12 2015-12-16 Agenus Inc. Impfstoff zur Behandlung und Prävention der Herpes Simplex-Virusinfektion

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2378094A2 (fr) * 1977-01-24 1978-08-18 Inst Nat Sante Rech Med Nouveaux reactifs biologiques constitues par des supports solides sur lesquels sont couples des composes organiques comportant un residu glucidique
US4196265A (en) * 1977-06-15 1980-04-01 The Wistar Institute Method of producing antibodies
JPS54113492A (en) * 1978-02-24 1979-09-05 Sanyo Chem Ind Ltd Preparation of glucoprotein derivative
CA1203164A (en) * 1982-03-09 1986-04-15 Thomas J. Mckearn Antibody conjugates
EP0117657A1 (de) * 1983-02-01 1984-09-05 Genentech, Inc. Tollwut-immunogene Polypeptide und davon abgeleitetes Vakzin, DNA-Sequenzen, Expressionsvektoren, rekombinante Zellen und Kulturen dafür sowie Verfahren zu deren Herstellung
FR2543570B1 (fr) * 1983-03-31 1985-08-09 Pasteur Institut Anticorps monoclonaux anticytomegalovirus humains, hybridomes secreteurs de ces anticorps et polypeptides porteurs d'un determinant antigenique sequentiel de cytomegalovirus humains
WO1984004327A1 (en) 1983-04-27 1984-11-08 Harvard College Method and products for detection of human t cell leukemia virus
US4634666A (en) * 1984-01-06 1987-01-06 The Board Of Trustees Of The Leland Stanford Junior University Human-murine hybridoma fusion partner
US4743553A (en) * 1984-07-18 1988-05-10 W. R. Grace & Co. Synthetic genes for bovine parainfluenza virus

Also Published As

Publication number Publication date
GR3003323T3 (en) 1993-02-17
FI873233A0 (fi) 1987-07-23
EP0229546A1 (de) 1987-07-22
WO1987003206A1 (en) 1987-06-04
FI873233A (fi) 1987-07-23
ES2038597T3 (es) 1993-08-01
ATE67314T1 (de) 1991-09-15
AU6723187A (en) 1987-07-01
EP0229546B1 (de) 1991-09-11
AU592142B2 (en) 1990-01-04

Similar Documents

Publication Publication Date Title
ZA868886B (en) Carbohydrate perturbations of viruses or viral antigens and utilization for diagnostic,prophylactic and/or therapeutic applications
DE68928119T2 (de) Non-A, non-B-Hepatitisvirus-Antigenpeptid
FI860284A0 (fi) Foerfarande foer diagnostisering av ledsjukdomar.
ATE340590T1 (de) Gegen menschliches interleukin-8 gerichteter, rekonstituierter menschlicher antikörper
NO873448L (no) Festeboeyle, saerlig for osteosyntese.
FI871288A0 (fi) Menetelmä aprotiniinin valmistamiseksi yhdistelmä-DNA-tekniikalla ja menetelmään soveltuva DNA, ilmentämisplasmidi ja isäntäsolu
DE3681428D1 (de) Stoerungen von karbohydraten in viren oder virusantigenen und verwendung in diagnostischen, prophylaktischen und/oder therapeutischen anwendungen.
CA2108259A1 (en) Process of screening plasma samples for effective antibody titers against respiratory viruses
ATE86633T1 (de) Snrnp-a-antigen und fragmente davon.
DE69030545D1 (de) Aufspüren und Behandeln von Infektionen durch Verwendung von Immunokonjukaten
DE3850634D1 (de) Alpha 2-3-Verbindungen erkennender monoklonaler Antikörper.
Jonsson et al. Immune complexes and complement components in Bell’s palsy
Julkunen et al. Elevated serum immune complex levels in Pogosta disease, an acute alphavirus infection with rash and arthritis.
Deutsch et al. A study of the complement fixing properties of equine antisera
FI903143A0 (fi) Menetelmä ihmisen nuhaviruksen serotyypittämiseksi
ES2013665A6 (es) Procedimiento para preparar un anticuerpo monoclonal humano y metodo de uso.
DE3850692D1 (de) Treponema hyodysenteriae-Antigen und seine Verwendungen.
SU1739559A1 (ru) Штамм вируса aphtae epizooticae типа o, используемый для изготовления диагностических сывороток и антигенных препаратов
IT8520740A0 (it) Procedimento per la concentrazione di virus da fluidi.
Ronneberger Assay of possible formation of antigenic components in heat-treated plasma protein preparations
Silverman et al. Characteristics of re-referred families in a child abuse program.
Peretz et al. About five cases of acute rheumatic fever in the adult
Oka Serum antibody titers of patients who had a positive test for the O-Ring(OR) reaction to a wide variety of viral infection
IL82563A0 (en) Carbohydrate perturbations of viruses or viral antigens and utilization for diagnostic,prophylactic and/or therapeutic applications
BR8205046A (pt) Anti-poluidor atmosferico com recuperacao de poeiras e vapores doces e,fuligens das torrefatoras

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee